reports
Onconova Therapeutics Inc: 4 directors bought
Four Directors at Onconova Therapeutics Inc bought 119,104 shares at between 0.256USD and 0.265USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
- Jonathan Moreland
WHR WHIRLPOOL CORPORATION
AYI ACUITY BRANDS INC.
STON STONEMOR INC.
SOHU SOHU.COM (N SHARES)
RDN RADIAN GROUP INC.
OPK OPKO HEALTH INC.
ONTX ONCONOVA THERAPEUTICS INC
MSTR MICROSTRATEGY INCORPORATED CLASS A
LKQ LKQ CORPORATION
A2N6GQ LEGACY RESERVES
KMPR KEMPER CORPORATION
IVAC INTEVAC INC.
HCAP HARVEST CAPITAL CREDIT CORP
FLDM FLUIDIGM
FAST FASTENAL COMPANY
ETM ENTERCOM COMMUNICATIONS CORP. CLASS A
ELS EQUITY LIFESTYLE PROPERTIES INC.
EBSB MERIDIAN BANCORP INC
CFMS CONFORMIS
A2AM8Y CARDTRONICS PLC CLASS A
BDGE BRIDGE BANCORP INC.
AXE ANIXTER INTERNATIONAL INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
AMP AMERIPRISE FINANCIAL INC.
ALXN ALEXION PHARMACEUTICALS INC.
AGFS AGROFRESH SOLUTIONS
BW BABCOCK & WILCOX ENTERPRISES
CFR CULLEN/FROST BANKERS INC.
CRI CARTER'S INC.
CRR CARBO CERAMICS INC.
DLTH DULUTH HOLDINGS INC. CLASS B
MRTN MARTEN TRANSPORT LTD.
OTEL OTELCO INC
WKHS WORKHORSE GROUP
X UNITED STATES STEEL CORPORATION
MX MAGNACHIP SEMICONDUCTOR CORP.
MMAC MMA CAPITAL HOLDINGS INC
CSTR CAPSTAR FINANCIAL HOLDINGS
SNAP SNAP INC. CLASS A
VERI VERITONE INC.
SAFE SAFETY INCOME & GROWTH
LBTYK LIBERTY GLOBAL PLC CLASS C
APPN APPIAN
PM PHILIP MORRIS INTERNATIONAL INC.
JOE ST JOE CO.
PHIL PHI GROUP INC.
NBN NORTHEAST BANCORP
ESRX EXPRESS SCRIPTS
DDR INC.
ELOX DEVELOPERS DIVERSIFIED REALTY CORPORATION
ABCP SEVION THERAPEUTICS
AMBASE CORP.
- Jonathan Moreland
OPK OPKO HEALTH INC.
ONTX ONCONOVA THERAPEUTICS INC
FAST FASTENAL COMPANY
ELS EQUITY LIFESTYLE PROPERTIES INC.
EBSB MERIDIAN BANCORP INC
AXE ANIXTER INTERNATIONAL INC.
CFR CULLEN/FROST BANKERS INC.
CRR CARBO CERAMICS INC.
MRTN MARTEN TRANSPORT LTD.
SAFE SAFETY INCOME & GROWTH
PM PHILIP MORRIS INTERNATIONAL INC.
JOE ST JOE CO.
PHIL PHI GROUP INC.
ESRX EXPRESS SCRIPTS
ELOX INC.
SEVION THERAPEUTICS
- Jonathan Moreland
WFC WELLS FARGO & COMPANY
TICC OXFORD SQUARE CAPITAL CORP
SYNL SYNALLOY CORP.
RDUS RADIUS HEALTH INC.
PBH PRESTIGE CONSUMER HEALTHCARE INC
OPK OPKO HEALTH INC.
ONTX ONCONOVA THERAPEUTICS INC
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
JWN NORDSTROM INC.
IVAC INTEVAC INC.
FLDM FLUIDIGM
EPC EDGEWELL PERSONAL CARE CO.
ENTA ENANTA PHARMACEUTICALS INC.
EGP EASTGROUP PROPERTIES INC.
BZH BEAZER HOMES USA INC.
BOCH BANK OF COMMERCE HOLDINGS
AHH ARMADA HOFFLER PROPERTIES INC.
BW BABCOCK & WILCOX ENTERPRISES
GRA W R GRACE & CO
CNBKA CENTURY BANCORP INC. CL A
T AT&T CORP.
GEMP GEMPHIRE THERAPEUTICS
NYMX NYMOX PHARMACEUTICAL CORP.
KALA KALA PHARMACEUTICALS INC.
PFIN P AND F INDUSTRIES
CHN THE CHINA FUND
CZWI INC.
PBIP CITIZENS COMMUNITY BANCORP (EAU CLAIRE
SLGD WI)
CTIC PRUDENTIAL BANCORP
MBL SCOTT'S LIQUID GOLD INC.
TRV CELL THERAPEUTICS
PHIL INC.
M B T FINANCIAL CORP.
THE TRAVELERS COMPANIES
INC.
PHI GROUP INC.
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Update: Moving forward
After receiving feedback from US and EU regulatory authorities, Onconova submitted a trial protocol in April with overall survival as the primary endpoint for its pivotal trial in myelodysplastic syndrome (MDS) patients. We remain confident of the ultimate success of rigosertib (IV), although we have taken a more conservative view of the launch timelines. As such, we have lowered our valuation to $171m or $7.91 per basic share, from $254m or $11.70 per share.
Update: The path forward for rigosertib (IV)
Onconova recently updated the scientific and investment communities on its development plans for rigosertib (IV) in myelodysplastic syndrome (MDS). While another Phase III trial will be necessary to gain FDA approval, European Medicines Agency (EMA) draft guidelines regarding subgroup analyses of clinical studies suggest a filing in Europe with the existing data may be possible. We expect clarity on the Phase III protocol necessary for US approval and the EU regulatory path in Q115. We have adju...
Update: Rigosertib (IV) on the way back
After meetings with the FDA and several European national regulatory agencies, Onconova has informed the investment community that it will pursue an indication of rigosertib IV in patients who are primary hypomethylating agents (HMA) failures, with the detailed pivotal trial design to be unveiled in Q414. We consider this a positive first step of rigosertib IV’s comeback from the failure of meeting the primary endpoint in the Phase III ONTIME trial. We have adjusted our valuation based on new ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.